Abstract

This study deals with observation on clinical therapeutic effect and toxic and side effects of capecitabine plus Fuzheng Jiedu decoction supplemented and reduced prescription for advanced gastric cancer. From January 2011 to January 2014, 145 patients with gastric cancer diagnosed by surgery, gastroscopy and pathology in our hospital, with measurable tumor lesions, were enrolled in this study. They were aged 45-85 y, with mean age (62.3 ± 6.7) y, 75 males and 70 females. In the study group, the disease progression time and survival time were 2-19.5 mo and 4.5-24 mo, respectively with 5 cases survived, while those of the control group were 1.5-20 months and 4.2-23 mo, respectively, with 3 cases survived. The t test showed no significant difference between the two groups (p>0.05). The survival rate of 60 cases within 1 y in    the study group (87.0 %) was significantly higher than that of the control group (59 cases, 77.9 %), and the difference was significant (p<0.05). The incidence rates of hand-foot syndrome, nausea and vomiting, diarrhea, abdominal pain, liver injury and neurotoxicity in the study group were 21.7 %, 2.9 %, 11.6 %, 7.2 %, 1.4 % and 17.4 %, which were significantly lower than that of the control group (43.4 %, 22.3 %, 25 %, 21.1 %, 11.8 % and 36.8 %) and the chi-square test showed a significant difference (p<0.05). Capecitabine plus Fuzheng Jiedu decoction supplemented and reduced prescription for treating advanced gastric cancer has a good therapeutic effect, less toxic and side effects and the patient’s quality of life is significantly improved. It is worthy of being popularized.